Last10K.com

Advansource Biomaterials Corp (ASNB) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, March 31, 2015

Advansource Biomaterials Corp

HISTORY TOOLS
CIK: 1011060 Ticker: ASNB
Document and Entity Information - USD ($)
12 Months Ended
Mar. 31, 2015
Jun. 17, 2015
Sep. 30, 2014
Document and Entity Information:   
Entity Registrant NameAdvansource Biomaterials Corp  
Document Type10-K  
Document Period End DateMar. 31, 2015  
Amendment Flagfalse  
Entity Central Index Key0001011060  
Current Fiscal Year End Date--03-31  
Entity Common Stock, Shares Outstanding 21,490,621 
Entity Public Float  $ 840,000
Entity Filer CategorySmaller Reporting Company  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Well-known Seasoned IssuerNo  
Document Fiscal Year Focus2015  
Document Fiscal Period FocusFY  
Trading Symbolasnb  

View differences made from one year to another to evaluate Advansource Biomaterials Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Advansource Biomaterials Corp.

Continue

Assess how Advansource Biomaterials Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Advansource Biomaterials Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Balance Sheets
Condensed Statements Of Cash Flows
Condensed Statements Of Operations
Consolidated Statements Of Stockholders' Equity
Compensation And Employee Benefit Plans
Concentrations Of Credit Risk And Major Customers
Contingencies
Description Of Business
Income Taxes
Income Taxes: Schedule Of Deferred Tax Assets And Liabilities (details)
Income Taxes: Schedule Of Deferred Tax Assets And Liabilities (tables)
Income Taxes: Schedule Of Effective Income Tax Rate Reconciliation (details)
Income Taxes: Schedule Of Effective Income Tax Rate Reconciliation (tables)
Income Taxes: Summary Of Operating Loss Carryforwards (tables)
Inventories
Inventories: Schedule Of Inventory (details)
Inventories: Schedule Of Inventory (tables)
License Agreements
Long-term Financing Obligation
Long-term Financing Obligation: Schedule Of Sale Leaseback Transactions (tables)
Promissory Note
Property, Plant And Equipment Disclosure
Property, Plant And Equipment Disclosure (details)
Property, Plant And Equipment Disclosure: Property, Plant And Equipment (details)
Property, Plant And Equipment Disclosure: Property, Plant And Equipment (tables)
Related Party Transactions Disclosure
Significant Accounting Policies
Significant Accounting Policies: Accounting Principles (policies)
Significant Accounting Policies: Accounts Receivable (policies)
Significant Accounting Policies: Advertising Costs (policies)
Significant Accounting Policies: Basic And Diluted Earnings (loss) Per Share (policies)
Significant Accounting Policies: Cash (policies)
Significant Accounting Policies: Deferred Financing Costs (policies)
Significant Accounting Policies: Fair Value Of Financial Instruments (policies)
Significant Accounting Policies: Impairment Of Long-lived Assets (policies)
Significant Accounting Policies: Income Taxes (policies)
Significant Accounting Policies: Inventories (details)
Significant Accounting Policies: Inventories (policies)
Significant Accounting Policies: New Accounting Pronouncements (policies)
Significant Accounting Policies: Property And Equipment (policies)
Significant Accounting Policies: Research, Development And Regulatory Expense (details)
Significant Accounting Policies: Research, Development And Regulatory Expense (policies)
Significant Accounting Policies: Revenue Recognition Accounting Policy (policies)
Significant Accounting Policies: Stock-based Compensation (policies)
Significant Accounting Policies: Use Of Accounting Estimates (policies)
Stock-based Compensation
Stock-based Compensation: Schedule Of Share-based Compensation Activity (tables)
Stockholders' Equity
Subsequent Events

Material Contracts, Statements, Certifications & more

Advansource Biomaterials Corp provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: ASNB
CIK: 1011060
Form Type: 10-K Annual Report
Accession Number: 0001011060-15-000009
Submitted to the SEC: Mon Jul 13 2015 9:44:09 PM EST
Accepted by the SEC: Tue Jul 14 2015
Period: Tuesday, March 31, 2015
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/asnb/0001011060-15-000009.htm